Physician profile
Elizabeth Schepp
NPI 1811331572
$19,218.64
in general payments reported to CMS, 2019-2025
35 companies · $3,790 in 2025
The $3,790 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,176 · 2020: $1,327 · 2021: $1,495 · 2022: $2,746 · 2023: $3,376 · 2024: $4,309 · 2025: $3,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,276.62 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,337.09 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,764.78 | 2019-2025 | Tremfya |
| Incyte Corporation | $1,422.90 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $1,351.74 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $1,159.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $1,118.29 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,091.22 | 2019-2025 | |
| Leo Pharma INC. | $995.27 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $957.84 | 2023-2025 | Zoryve |
| Genzyme Corporation | $946.42 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $755.07 | 2019-2025 | Ilumya |
| Galderma Laboratories, L.P. | $648.10 | 2019-2025 | Aklief, Oracea, Nemluvio |
| Pfizer INC. | $630.86 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $463.88 | 2019-2025 | Siliq, Duobrii, Jublia |
| Dermavant Sciences, INC. | $412.17 | 2023-2024 | Vtama |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $363.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $360.88 | 2022-2025 | Sotyktu |
| Ucb, INC. | $345.62 | 2019-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $253.82 | 2019-2025 | |
| Almirall LLC | $221.38 | 2020-2025 | Klisyri, Seysara |
| Epi Health, LLC | $183.35 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $55.09 | 2020-2021 | |
| Biofrontera INC. | $45.61 | 2019-2022 | |
| Hill Dermaceuticals, INC. | $44.91 | 2021 | |
| Genentech USA, INC. | $44.25 | 2020-2024 | Erivedge |
| Encore Dermatology INC. | $44.24 | 2019-2020 | |
| Dermira, INC. | $40.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.46 | 2023 | Spevigo |
| Journey Medical Corporation | $26.95 | 2020 | |
| Organon LLC | $26.70 | 2025 | Vtama |
| Tempus Ai, INC | $26.59 | 2024 | Merlin Test |
| Sebela Pharmaceuticals INC. | $18.50 | 2019 | |
| Elekta, INC. | $16.70 | 2025 | Flexitron Hdr |
| Melinta Therapeutics, LLC | $11.57 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $3.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Schepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.